Ivermectin decreases inflammation and imiquimod–induced psoriasis-like skin lesions in rat via targeting TLR۴ / p۶۵ NF-κB

سال انتشار: 1404
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 94

فایل این مقاله در 7 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IJBMS-28-6_014

تاریخ نمایه سازی: 26 فروردین 1404

چکیده مقاله:

Objective(s): Psoriasis is a chronic skin disease that usually manifests as white and silver spots on the skin. Because of its anti-inflammatory properties, we investigated the effects of ivermectin (IVM) on imiquimod (IMQ)-induced psoriasis in rats.Materials and Methods: Fifteen rats were assigned to ۳ different groups (n=۵ per group): the control group received normal water and food; the psoriasis group, in which psoriasis was induced by topical application of IMQ (۱ mg per rat), and treatment group where rats were treated daily with topical IVM-gel (۱%) from day ۳ to ۷. The Psoriasis Area Severity Index (PASI) Score for the entire treatment period was used to assess erythema, silver scale, and skin thickness on the dorsal region of rats, and the spleen-to-body weight index on day ۷ was examined. Moreover, histological assessment of skin tissues was performed using fluorescence immunostaining and hematoxylin-eosin (H&E) staining. Results: The severity of lesions in the ivermectin group was reduced compared to the IMQ group, with a significant decrease in the average PASI scores. The results of fluorescence immunostaining showed that topical administration of IVM-gel reduced inflammation by decreasing Toll-like receptor ۴ (TLR۴) levels and p۶۵ nuclear factor kappa-B (NF-κB). Furthermore, findings from H&E staining revealed that IVM-gel decreased dermal fibrosis, epidermal thickness, and infiltration of inflammatory cells caused by IMQ. Conclusion: Based on the obtained results, it can be concluded that IVM-gel can effectively reduce psoriasis lesions due to its therapeutic properties, such as anti-inflammatory effects via targeting TLR۴/p۶۵ NF-κB.

کلیدواژه ها:

نویسندگان

Tayebeh Noori

Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran

Antoni Sureda

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), ۲۸۰۲۹ Madrid, Spain

Samira Shirooie

Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Chen S, Li H, Liu Y, Zhu Z, Wei Q. ...
  • Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, ...
  • Kaffenberger BH, Lee GL, Tyler K, Chan DV, Jarjour W, ...
  • Unissa R, Kumar PM, Pasha M, Begum S, Maheswari B. ...
  • Chen Y, Zhang Q, Liu H, Lu C, Liang C-L, ...
  • Ansar A, Emami Z. Evaluation of serum prolactin level in ...
  • Sangaraju R, Alavala S, Nalban N, Jerald MK, Sistla R. ...
  • Yousefi-Manesh H, Noori T, Asgardoon MH, Derakhshan MH, Tavangar SM, ...
  • Tanhapour M, Falahi B, Vaisi‐Raygani A, Bahrehmand F, Kiani A, ...
  • Nie L, Cai S-Y, Shao J-Z, Chen J. Toll-like receptors, ...
  • Chen J-Q, Szodoray P, Zeher M. Toll-like receptor pathways in ...
  • Botten G, Scumpia P, Doty K, Smale S. Global regulation ...
  • Panzer R, Blobel C, Fölster‐Holst R, Proksch E. TLR ۲ ...
  • Pochernina VV, Daschuk AM. TLR expression on peripheral blood monocytes ...
  • Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei X-Y, ...
  • Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling ...
  • Ortiz-Lopez LI, Choudhary V, Bollag WB. Updated perspectives on keratinocytes ...
  • Zhou X, Chen Y, Cui L, Shi Y, Guo C. ...
  • Gao J, Chen F, Fang H, Mi J, Qi Q, ...
  • Goldminz A, Au S, Kim N, Gottlieb A, Lizzul P. ...
  • Andrés RM, Montesinos MC, Navalón P, Payá M, Terencio MC. ...
  • El Malki K, Karbach SH, Huppert J, Zayoud M, Reißig ...
  • Hammerl V, Parlar B, Navarini A, Gantenbein L, Väth H, ...
  • Sinx KA, Nelemans PJ, Kelleners-Smeets NW, Winnepenninckx VJ, Arits AH, ...
  • Sharma M, Sharma G, Singh B, Katare O. Actinic keratosis ...
  • Chamcheu JC, Chaves-Rodriquez M-I, Adhami VM, Siddiqui IA, Wood GS, ...
  • Zeng Y, Zhao H, Zhang T, Zhang C, He Y, ...
  • Jabeen M, Boisgard A-S, Danoy A, El Kholti N, Salvi ...
  • Gupta M, Agrawal U, Vyas SP. Nanocarrier-based topical drug delivery ...
  • Sonawane R, Harde H, Katariya M, Agrawal S, Jain S. ...
  • Mitra A, Wu Y. Topical delivery for the treatment of ...
  • Padivitage N, Adhikari S, Rustum AM. Assay of ivermectin including ...
  • Laing R, Gillan V, Devaney E. Ivermectin–old drug, new tricks?. ...
  • Sharun K, Dhama K, Patel SK, Pathak M, Tiwari R, ...
  • Yan S, Ci X, Chen N, Chen C, Li X, ...
  • Ventre E, Rozières A, Lenief V, Albert F, Rossio P, ...
  • Schaller M, Gonser L, Belge K, Braunsdorf C, Nordin R, ...
  • Thibaut de Ménonville S, Rosignoli C, Soares E, Roquet M, ...
  • Hebeish A, Hashem M, Abd El-Hady M, Sharaf S. Development ...
  • Basu P, Repanas A, Chatterjee A, Glasmacher B, NarendraKumar U, ...
  • Basu P, Narendrakumar U, Arunachalam R, Devi S, Manjubala I. ...
  • Ahmad H. Celluloses as support materials for antibacterial agents: a ...
  • Rahman M, Hasan M, Nitai AS, Nam S, Karmakar AK, ...
  • Costa EM, Pereira CF, Ribeiro AA, Casanova F, Freixo R, ...
  • Zhang W, Liu Y, Xuan Y, Zhang S. Synthesis and ...
  • Zimmermann M. Ethical guidelines for investigations of experimental pain in ...
  • Saka R, Jain H, Kommineni N, Chella N, Khan W. ...
  • Maher A, Radwan R, Breitinger H-G. In vivo protection against ...
  • Zeini MS, Haddadi N-S, Shayan M, Zeini MS, Kazemi K, ...
  • Yousefi-Manesh H, Dehpour AR, Nabavi SM, Khayatkashani M, Asgardoon MH, ...
  • Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: ...
  • Branisteanu DE, Voicu CM, Cretu A, Dimitriu A, Luca MC, ...
  • Meng FZ, Liu JB, Wang X, Wang P, Hu WH, ...
  • Moos S, Mohebiany AN, Waisman A, Kurschus FC. Imiquimod-induced psoriasis ...
  • Benhadou F, Mintoff D, Del Marmol V. Psoriasis: keratinocytes or ...
  • Garzorz-Stark N, Eyerich K. Psoriasis pathogenesis: keratinocytes are back in ...
  • Alexander H, Nestle FO. Pathogenesis and immunotherapy in cutaneous psoriasis: ...
  • Girolomoni G, Strohal R, Puig L, Bachelez H, Barker J, ...
  • Jabeen M, Boisgard AS, Danoy A, El Kholti N, Salvi ...
  • Steinhoff M, Vocanson M, Voegel JJ, Hacini-Rachinel F, Schäfer G. ...
  • Stein L, Kircik L, Fowler J, Tan J, Draelos Z, ...
  • Aryannejad A, Tabary M, Noroozi N, Mashinchi B, Iranshahi S, ...
  • Ye Y, Wang P, Zhou F. miR-۴۸۹-۳p inhibits TLR۴/NF-κB signaling ...
  • Malan M, Xuejingzi W, Quan SJ. Nuclear factor-kappa B (NF-ҡB) ...
  • Wei W, Dejie L, Xiaojing S, Tiancheng W, Yongguo C, ...
  • Korman NJ. Management of psoriasis as a systemic disease: what ...
  • Lv J, Wang Y, Xu J, Zhou T, Chen Z, ...
  • Cao C, Yin C, Chai Y, Jin H, Wang L, ...
  • نمایش کامل مراجع